Skip to main content
Fig. 1 | Trials

Fig. 1

From: A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial

Fig. 1

a Scheduled to receive 45 Gy–55 Gy long-course radiotherapy. b Treatment decision should be made prior to registration (planned choice is a randomisation stratification variable). Medical oncologist may choose to use CAPOX or FOLFOX, or single-agent capecitabine or 5-FU if concomitant use of oxaliplatin is contraindicated. c Patient defers surgery then the remaining 12 weeks of chemotherapy should be given as soon as possible following the repeat magnetic resonance imaging (MRI) scan and multidisciplinary team (MDT) meeting

Back to article page

Trials

ISSN: 1745-6215